IP Verse

Dana Farber Cancer Institute competitive analysis

Loading summary...

Latest patents of Dana Farber Cancer Institute opposed by its competitors

Explore Dana Farber Cancer Institute's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3506884
Sep 25, 2024Drug Delivery Compositions And Uses Thereof1
EP3023788
Feb 12, 2020Compositions Of Tumor Specific Neoantigens1
EP2423331
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2439284
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2439285
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2447375
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2397155
Dec 13, 2017Methods And Compositions For The Treatment Of Persistent Infections And Cancer By Inhibiting The Programmed Cell Death 1 (Pd-1)Pathway3
EP2133365
May 17, 2017Compositions And Methods For The Treatment Of Infections And Tumors1

Latest publications and patents of Dana Farber Cancer Institute New

Explore the latest publications and patents granted to Dana Farber Cancer Institute, showcasing their recent innovations and technological advancements.

Last updated on: Oct 17, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Dana Farber Cancer Institute

EP3576742
Jul 2, 2025Compounds, Compositions And Methods For Cancer TreatmentGranted And Under Opposition
EP3506884
Sep 25, 2024Drug Delivery Compositions And Uses ThereofPatent Maintained As Amended
EP3023788
Feb 12, 2020Compositions Of Tumor Specific NeoantigensGranted And Under Opposition
EP2447375
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting TreatmentsGranted And Under Opposition
EP2439285
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting TreatmentsGranted And Under Opposition
EP2439284
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting TreatmentsGranted And Under Opposition
EP2423331
May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting TreatmentsGranted And Under Opposition
EP2580322
Jan 10, 2018A Mek 1 Mutation Conferring Resistance To Raf And Mek InhibitorsNo Opposition Filed Within Time Limit
EP2545189
Jan 10, 2018Full Cold-Pcr Enrichment With Reference Blocking SequenceNo Opposition Filed Within Time Limit
EP2440559
Jan 10, 2018Egfr Inhibitors And Methods Of Treating DisordersNo Opposition Filed Within Time Limit

Latest PTAB cases involving Dana Farber Cancer Institute

Discover the latest PTAB cases involving Dana Farber Cancer Institute, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 23, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Dana Farber Cancer Institute

IPR2023-00501Feb 6, 2023DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2023-00249Dec 29, 2022DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2023-00252Dec 29, 2022DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
PGR2021-00115Aug 24, 2021KYMERA THERAPEUTICSDANA FARBER CANCER INSTITUTEInstitution Denied

Peer Comparison New

IP litigation analysis comparing Dana Farber Cancer Institute with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
DANA FARBER CANCER INSTITUTE - 1431
BOULT WADE TENNANT52 - - -
BRISTOL MYERS SQUIBB - 67 - 8
JAMES POOLE153 - - -